Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders. The Current indications under development are ...

In this video from the American Academy of Ophthalmology meeting, Lejla Vajzovic, MD, FASRS, highlights a presentation on macular telangiectasia type 2.

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that i ...

Only cases of alleged murder, rape or manslaughter will be decided by a jury under new proposals to cut court backlogs.

Two oral, and five poster presentations will showcase the company’s progress in developing allogenic cell therapy candidates for multiple ...

LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that Heather Turner, Chief ...

The government's plans to ease record crown court backlogs have been described as a "worrying price to pay to improve ...

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...

RVPH READ THE FULL RVPH RESEARCH REPORT Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 3Q:25 results, confirming ...

Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced that its first results from the ongoing inMMyCAR study, a Phase 1 clinical trial ...

Controversial plans to scrap jury trials except in the most serious cases have surfaced - on the same day a Kent judge ...